Hot Features
Premium
Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 337 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Acrivon Therapeutics Inc | ACRV | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.07 | -0.83% | 8.40 | 04:40:35 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.47 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 14 | 337 | - | 3.19 - 14.30 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 04:40:35 | formt | 272 | US$ 8.40 | USD |
Acrivon Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 187.99M | 22.19M | - | 0 | -60.39M | -2.72 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Acrivon Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACRV Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 10.24 | 10.77 | 7.80 | 9.20 | 453,255 | -1.84 | -17.97% |
| 1 Month | 7.09 | 11.90 | 5.70 | 9.61 | 2,311,419 | 1.31 | 18.48% |
| 3 Months | 3.76 | 11.90 | 3.19 | 9.26 | 817,711 | 4.64 | 123.40% |
| 6 Months | 5.40 | 11.90 | 3.19 | 9.02 | 400,056 | 3.00 | 55.56% |
| 1 Year | 12.13 | 14.30 | 3.19 | 9.15 | 209,157 | -3.73 | -30.75% |
| 3 Years | 13.89 | 25.47 | 3.19 | 10.07 | 163,671 | -5.49 | -39.52% |
| 5 Years | 13.89 | 25.47 | 3.19 | 10.07 | 163,671 | -5.49 | -39.52% |
Acrivon Therapeutics Description
| Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. |
